&w=3840&q=100)
World Hypertension Day 2025: History, theme, summer foods for BP management
World Hypertension Day is observed every May 17 to raise awareness about the dangers of high blood pressure and promote healthier living. The day serves as a global reminder of the importance of monitoring blood pressure regularly and understanding the serious health risks associated with hypertension.
Marked by campaigns and health initiatives worldwide, the aim is to highlight how unchecked hypertension can lead to severe complications such as heart disease, stroke, kidney failure, and other life-threatening conditions. The observance also encourages people to adopt preventive measures through regular screenings and lifestyle changes.
World Hypertension Day 2025: Theme
"Measure Your Blood Pressure Accurately, Control It, Live Longer" is the theme for World Hypertension Day 2025. Every year, World Hypertension Day is observed with a theme highlighting a key aspect of managing, preventing, or raising hypertension awareness.
World Hypertension Day: History
World Hypertension Day was established in 2005 by the World Hypertension League (WHL), a non-governmental organisation dedicated to addressing the global health crisis posed by high blood pressure. The WHL launched the initiative to raise public awareness about hypertension and its potentially serious consequences, aiming to promote early detection, prevention, and management of the condition worldwide.
This day has gained international recognition due to the growing importance of this condition, and an increasing number of governments, non-profit organisations, and health organisations are joining the effort to emphasise the significance of blood pressure management.
Significance of World Hypertension Day
Hypertension is sometimes called the "silent killer" since it typically does not show until the heart, kidneys, or brain have been seriously damaged. The World Health Organisation (WHO) estimates that 1.13 billion people worldwide suffer from excessive blood pressure.
Sadly, a large number of them remain undiagnosed or untreated, putting them at risk for major health problems. Therefore, the WHL aimed to decrease the number of people experiencing difficulties from uncontrolled hypertension and to educate the public. It is a wake-up call for communities, people, and healthcare systems.
Hypertension Day special: Best 5 summer foods that can help your BP management
1. Cucumber
Cool cucumbers in summers are great for lowering blood pressure. Low in calories and high in potassium, they aid in blood vessel relaxation and the excretion of excess salt through urine, both of which are essential for preserving healthy blood pressure levels.
2. Tomatoes
Lycopene, an antioxidant not only lowers BP but also reduces risk of heart disease, is abundant in juicy summer tomatoes. They are a heart-healthy addition to salads, soups, or even drinks during the hot season because they also contain potassium and vitamin C.
3. Leafy greens
Nitrates, which are abundant in many summer greens, help the body produce nitric oxide, which widens blood vessels and lowers blood pressure. Additionally, they are rich in potassium and magnesium, two essential elements that promote heart health.
4. Lemons
On a hot day, a drink of lemon water is not only refreshing but also therapeutic. Vitamin C and flavonoids found in lemons aid in vascular health and inflammation reduction. They also help the body eliminate extra sodium by acting as a mild diuretic.
5. Garlic
Garlic is a simple addition to many summer recipes, but it is not seasonal. Allicin, a substance that relaxes blood arteries and lowers blood pressure, is present in it. There are quantifiable advantages to using raw garlic in salads or dips.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
2 hours ago
- Business Standard
Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate
Bharat Biotech on Thursday announced its partnership with UK-based pharma company GSK for the development and potential use of the Shigella vaccine candidate altSonflex1-2-3. As part of the agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory advancement and large-scale manufacturing. GSK, on the other hand, will support the programme by assisting with clinical trial design, securing external funding and contributing to the access and delivery plans and commercialisation strategy. The company said that the agreement marks a significant step in advancing the vaccine, which targets shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five years of age in low- and middle-income countries (LMICs). 'The vaccine candidate has already demonstrated a strong safety and immunogenicity profile in both European and African trials, including in the primary target population of nine-month-old infants,' it added. Commenting on the development, Krishna Ella, Executive Chairman at Bharat Biotech, said that with no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on LMICs. 'This collaboration combines our strengths in innovation, manufacturing and global health commitment.' According to the World Health Organisation (WHO), Shigella was the second-leading cause of diarrhoeal mortality in 2016 (latest data) among all ages and the leading bacterial cause of diarrhoea, accounting for approximately 212,000 deaths and about 13 per cent of all diarrhoea-associated deaths. The disease is a major contributor to child morbidity and mortality, and the emergence of drug-resistant strains underscores the urgent need for a preventive vaccine. The standard of care for shigellosis primarily involves managing dehydration and using antibiotics. While mild cases often resolve with rest and fluid replacement, more severe cases or those with weakened immune systems may benefit from antibiotics like ciprofloxacin or azithromycin. Thomas Breuer, Chief Global Health Officer at GSK, said that by helping reduce illness and antibiotic use, this vaccine has the potential to play a critical role in combating antimicrobial resistance (AMR). The companies claimed that the vaccine candidate has broad serotype coverage, an innovative Generalised Modules for Membrane Antigens (GMMA)-based platform and robust early clinical results. 'GMMA technology is a platform that uses bacterial outer membranes to deliver the O antigen to the immune system, allowing for high-yield production, which creates affordable vaccines for underserved populations,' they added in a statement.


United News of India
10 hours ago
- United News of India
India reports 7,151 active Covid-19 cases; six new deaths in last 24 hrs
New Delhi, June 12 (UNI) India's total number of Covid-19 cases has reached 7,151 as of 8 AM on Thursday, according to the Ministry of Health and Family Welfare. In the past 24 hours, 33 new infections have been confirmed, though case data from West Bengal is still awaited. Additionally, six new deaths linked to Covid-19 were reported in the last 24 hours: three from Kerala, two from Karnataka, and one from Maharashtra. These bring the total number of Covid-related deaths in 2025 to 74. On a positive note, more than 8,000 individuals have recovered from the virus so far this year. While several states have reported modest increases in active cases, Kerala remains the worst affected, with 2,223 active infections as of Thursday. Other states with relatively high caseloads include Gujarat, West Bengal, Delhi, and Maharashtra, based on data from the national COVID-19 dashboard. Health authorities attribute the current rise in infections to new Omicron sub-variants including JN.1, NB.1.8.1, LF.7, and XFC. These strains are noted for their high transmissibility but are causing milder illness compared to earlier variants. The World Health Organisation (WHO) has classified them as "Variants Under Monitoring", indicating that while they are not currently a serious threat, their progress should be observed closely. Covid-19, caused by the SARS-CoV-2 virus, has now transitioned into a seasonal pattern similar to the flu. Though no longer considered an emergency, the virus continues to circulate and may pose risks, especially to vulnerable populations. UNI AJ ARN


Hindustan Times
12 hours ago
- Hindustan Times
New Covid-19 variant causes sore throat that feels like 'razor blades': Everything to know about NB.1.8.1 aka Nimbus
The variant, NB.1.8.1, has been informally dubbed 'Nimbus' and causes a severe sore throat that's been likened to 'razor blades'. The World Health Organisation (WHO) is monitoring it, as this latest mutation of the contagious virus already makes up over 10 percent of cases in Asia, Salon said in a June 11 report. The portal added that NB.1.8.1 has now been detected in multiple countries, including the US and Canada. Also read | Covid-19 comeback: Here's why coronavirus is spreading again and new symptoms you should watch out for The Covid-19 variant NB.1.8.1, also known as Nimbus, is a descendant of the Omicron family and has been classified as a Variant Under Monitoring (VUM) by the WHO. To mitigate the spread of NB. 1.8.1, it's essential to practice good respiratory hygiene, maintain social distancing, and follow public health guidelines. Salon reported that this strain causes 'razor blade throat' or a severe sore throat. Other symptoms include flu-like symptoms such as congestion, fatigue, a mild cough, fever, and muscle aches, and more infrequently diarrhoea and nausea, The Independent said in a June 10 report. Per that portal, WHO says global risk is 'currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease'. Salon said that Nimbus has recombined genetic material from other strains three times – although the process of recombination is a natural process of viruses trying to evolve to survive among the population, recombination events are concerning because each time a virus does so, it has the potential to evolve into something that is more infectious or causes more severe disease. The portal quoted Dr Rajendram Rajnarayanan of the New York Institute of Technology campus in Jonesboro, Arkansas, as having said that one of these mutations in Nimbus allows it to evade the immunity we have built against the virus from prior infections, so transmissibility might be slightly higher. Dr Rajnarayanan also said: 'We haven't seen a big surge in emergency departments due to Covid-related conditions and respiratory things in this term yet. We have to wait and watch.' Dr T Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, added, 'We learned from Omicron that high transmissibility can cause as much damage as high per infection virulence, and at this point it is not just acute severity that is of concern, but longer-term impacts of repeated infection.' Such impacts include conditions like 'long Covid', in which the symptoms of Covid-19 last for months or years, often disabling patients, the report added. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.